{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-005108","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2023-01-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.474599+00:00","generated_at":"2026-06-20T09:50:07.205957+00:00","sec_items":["1.01","3.02","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Cadrenal Therapeutics completes $7M IPO at $5/share and receives FDA Fast Track for tecarfarin","bullets":["IPO of 1.4M shares at $5.00 closed Jan 24, raising $7.0M gross; stock trades on Nasdaq as CVKD.","FDA granted Fast Track designation for tecarfarin in ESRD and atrial fibrillation patients.","Appointed directors: Glynn Wilson (Class I), John Murphy (Class II), Steven Zelenkofske (Class III).","Employment agreements: CFO Szot ($375K salary, 50% target bonus); CMO Losordo ($425K, 40% bonus).","Issued 600K shares to HESP LLC, 1.14M on note conversion, 250K on warrant exercise."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-005108","json":"https://secwatch.observer/filing/0001213900-23-005108.json","markdown":"https://secwatch.observer/filing/0001213900-23-005108.md","text":"https://secwatch.observer/filing/0001213900-23-005108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/ea172140-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T09:50:07.205957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1405e77c3e","claim":"Douglas Losordo was appointed as Chief Medical Officer at Cadrenal Therapeutics, Inc..","evidence_excerpt":"Upon completion of the IPO, we entered into an employment agreement with each of Matthew Szot, the Company’s Chief Financial Officer, and Douglas Losordo, the Company’s Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"4052867c32","claim":"Steven Zelenkofske was appointed as Class III Director at Cadrenal Therapeutics, Inc..","evidence_excerpt":"Steven Zelenkofske was appointed as a Class III director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"6754af6238","claim":"John Murphy was appointed as Class II Director at Cadrenal Therapeutics, Inc..","evidence_excerpt":"John Murphy was appointed as a Class II director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"8defc9c338","claim":"Matthew Szot was appointed as Chief Financial Officer at Cadrenal Therapeutics, Inc..","evidence_excerpt":"Upon completion of the IPO, we entered into an employment agreement with each of Matthew Szot, the Company’s Chief Financial Officer, and Douglas Losordo, the Company’s Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"9e1be76a04","claim":"Glynn Wilson was appointed as Class I Director at Cadrenal Therapeutics, Inc..","evidence_excerpt":"Glynn Wilson was appointed as a Class I director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"745b302bb0e20dd74f1d1e94cf8c3b8640813b20","claim":"Cadrenal Therapeutics, Inc. entered into Underwriting Agreement with Boustead Securities, LLC (as representative of the underwriters) valued at Gross proceeds of $7,000,000 from sale of 1,400,000 shares at $5.00 per share; Representative's Warr (effective 2023-01-19).","evidence_excerpt":"On January 19, 2023, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Boustead Securities, LLC, as representative of the underwriters (the “Representative”), a form of which was previously filed as an exhibit to the Company’s registration statement on Form S-1, as amended (File No. 333-267562), which was declared effective by the Securities and Exchange Commission (the “Commission”) on January 19, 2023 (the “Registration Statement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Boustead Securities, LLC (as representative of the underwriters)"},{"label":"Value","value":"Gross proceeds of $7,000,000 from sale of 1,400,000 shares at $5.00 per share; Representative's Warr"},{"label":"Effective","value":"2023-01-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}